Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N04 ANTI-PARKINSON DRUGS
N04B DOPAMINERGIC AGENTS
N04BX Other dopaminergic agents
N04BX02 Entacapone
D00781 Entacapone (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antiparkinson Agents
Antiparkinson Agents, Other
Entacapone
D00781 Entacapone (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
116 Antiparkinsonian agents
1169 Others
D00781 Entacapone (JP18/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01497 Catechol O-methyltransferase inhibitor
D00781 Entacapone
DG01967 Antiparkinson agent
DG02909 COMT inhibitor
D00781 Entacapone
Metabolizing enzyme inhibitor
DG01643 CYP2C9 inhibitor
D00781 Entacapone
Drug classes [BR:br08332]
Neuropsychiatric agent
DG01967 Antiparkinson agent
D00781 Entacapone
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Methyltransferases
COMT
D00781 Entacapone (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00781 Entacapone
D00781 Entacapone tablets
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00781
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00781
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00781
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00781
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00781